Actively Recruiting
Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Led by Dr. Anne Conlin · Updated on 2025-05-30
24
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
Sponsors
D
Dr. Anne Conlin
Lead Sponsor
U
University of Ottawa
Collaborating Sponsor
AI-Summary
What this Trial Is About
Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV. Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.
CONDITIONS
Official Title
Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give informed consent
- Willing to follow all study procedures and be available for the entire study
- Adults 18 years or older
- Male or female
- Presenting to the emergency department with active, spontaneous nosebleed (anterior or posterior)
You will not qualify if you...
- Had sinonasal surgery within the last month
- Received medical treatment for nosebleeds in the last 30 days
- Septum perforation
- Known bleeding disorders such as thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease
- History of blood clots or thromboembolic disease including stroke or transient ischemic attack
- Known central nervous system diseases including seizures or brain lesions
- History of serious skull base injury or cerebrospinal fluid leak
- Known color vision problems
- Known blood in urine or kidney-related bleeding
- Pregnant or breastfeeding
- Known allergy or sensitivity to the study medication
- Signs or symptoms of serious emergency conditions like heart attack, stroke, major trauma, shock, or unstable blood pressure
- Cognitive impairment or substance abuse
- Any condition that may pose a risk, affect reliability, or interfere with study assessments
- Currently participating in another interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peterborough Regional Health Centre
Peterborough, Ontario, Canada, K9J 7C6
Actively Recruiting
Research Team
A
Anne Conlin, HBA&Sc, MD, FRCSC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here